Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial

• Hauptverfasser: Kristian Reich (Verfasst von), Lars Erik Kristensen (Verfasst von), Saxon D. Smith (Verfasst von), Phoebe Rich (Verfasst von), Christophe Sapin (Verfasst von), Soyi Liu Leage (Verfasst von), Robert McKenzie (Verfasst von), Christopher Schuster (Verfasst von), Elisabeth Riedl (Verfasst von), Melinda Gooderham (Verfasst von)
• Format: Buch
• Veröffentlicht: Mattioli1885, 2022-05-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Introduction: The randomised, open-label, assessor-blinded, parallel-group SPIRIT-H2H trial (NCT03151551) demonstrated superiority of ixekizumab over adalimumab in simultaneously achieving improvement in joint symptoms (American College of Rheumatology [ACR]50) and clearance of skin lesions (Psorias...